Paroxysmal Nocturnal Hemoglobinuria (PNH)
Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis
Introduction: Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal he
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Iptacopan Iptacopan: FABHALTA, a complement factor B inhibitor, is the first oral medication approved to treat adults with paroxysmal nocturnal hemoglobinuria (PNH). It was approved by the U.S.
Michael Drazer, MD, PhD
Institution
University of Chicago
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Michael Drazer, MD, PhD, is a hematologist/oncologist and geneticist specializing in the care of people with blood disorders, blood cancers, hereditary blood disorders, and hereditary cancer syndromes. He runs one of the only clinics in the world focused on the care of people with hereditary blood cancer syndromes. Dr. Drazer's laboratory research focuses on determining the mechanisms that drive hereditary blood and cancer syndromes, with a particular emphasis on developing "high fidelity" cellular and mouse models of these disorders. He is also heavily involved in the discovery of novel
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
Crovalimab Crovalimab: An experimental complement inhibitor C5 monoclonal antibody.
Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria
Introduction: Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal he
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
Crovalimab Crovalimab: An experimental complement inhibitor C5 monoclonal antibody.